[go: up one dir, main page]

BR9812716A - Métodos para formação de imagem para diagnóstico de contraste intensificado para monitorar terapias interventivas - Google Patents

Métodos para formação de imagem para diagnóstico de contraste intensificado para monitorar terapias interventivas

Info

Publication number
BR9812716A
BR9812716A BR9812716-0A BR9812716A BR9812716A BR 9812716 A BR9812716 A BR 9812716A BR 9812716 A BR9812716 A BR 9812716A BR 9812716 A BR9812716 A BR 9812716A
Authority
BR
Brazil
Prior art keywords
contrast
monitor
tissue
diagnosis
state
Prior art date
Application number
BR9812716-0A
Other languages
English (en)
Inventor
Randall B Lauffer
Stephen O Dunham
Original Assignee
Epix Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epix Medical Inc filed Critical Epix Medical Inc
Publication of BR9812716A publication Critical patent/BR9812716A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Transforming Light Signals Into Electric Signals (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)

Abstract

Patente de Invenção: <B>"MéTODOS PARA FORMAçãO DE IMAGEM PARA DIAGNóSTICO DE CONTRASTE INTENSIFICADO PARA MONITORAR TERAPIAS INTERVENTIVAS"<D>. A presente invenção refere-se à um método para formação de imagem para diagnóstico de contraste intensificado para monitorar a eficácia de terapias interventivas. Os agentes de contraste úteis para este método contêm uma porção intensificadora de imagem (IEM) e uma porção de ligação ao tecido dependente do estado (SDTBM). Esses agentes de contraste exibem ligação dependente do estado a um ou mais componentes e proporcionam uma mudança detectável nas características do sinal do agente de contraste uma vez ligado ao tecido ou componente do tecido alvo. Como resultado, esses agentes exibem uma afinidade de ligação para, e desse modo contraste de imagem, com o tecido alvo que se altera à medida que o estado do tecido se altera durante a terapia.
BR9812716-0A 1997-10-02 1998-09-24 Métodos para formação de imagem para diagnóstico de contraste intensificado para monitorar terapias interventivas BR9812716A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94298997A 1997-10-02 1997-10-02
PCT/US1998/020182 WO1999017809A2 (en) 1997-10-02 1998-09-24 Contrast-enhanced diagnostic imaging method for monitoring interventional therapies

Publications (1)

Publication Number Publication Date
BR9812716A true BR9812716A (pt) 2000-08-22

Family

ID=25478927

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9812716-0A BR9812716A (pt) 1997-10-02 1998-09-24 Métodos para formação de imagem para diagnóstico de contraste intensificado para monitorar terapias interventivas

Country Status (19)

Country Link
US (2) US6861045B1 (pt)
EP (1) EP1019094B1 (pt)
JP (2) JP2001518523A (pt)
KR (1) KR20010030854A (pt)
AT (1) ATE254479T1 (pt)
AU (1) AU742438C (pt)
BR (1) BR9812716A (pt)
CA (1) CA2303426C (pt)
DE (1) DE69819925T2 (pt)
DK (1) DK1019094T3 (pt)
ES (1) ES2206996T3 (pt)
HU (1) HUP0101245A3 (pt)
IL (1) IL134985A0 (pt)
IS (1) IS2041B (pt)
NO (1) NO321966B1 (pt)
NZ (1) NZ503402A (pt)
PT (1) PT1019094E (pt)
SK (1) SK4842000A3 (pt)
WO (1) WO1999017809A2 (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495118B1 (en) 1997-09-26 2002-12-17 Schering Aktiengesellschaft Lipophilic metal complexes for necrosis and infarction imaging
CA2303426C (en) * 1997-10-02 2008-09-23 Epix Medical, Inc. Contrast-enhanced diagnostic imaging method for monitoring interventional therapies
US6167297A (en) * 1999-05-05 2000-12-26 Benaron; David A. Detecting, localizing, and targeting internal sites in vivo using optical contrast agents
US6548044B1 (en) 1999-11-22 2003-04-15 Epix Medical, Inc. Imaging sexual response
JP2003520255A (ja) * 2000-01-22 2003-07-02 エピックス メディカル， インコーポレイテッド 酵素的な切断によって生理活性化される造影剤プロドラッグを使用した磁気共鳴画像法
TWI221406B (en) 2001-07-30 2004-10-01 Epix Medical Inc Systems and methods for targeted magnetic resonance imaging of the vascular system
US7186797B2 (en) * 2001-08-10 2007-03-06 Epix Pharmaceuticals, Inc. Polypeptide conjugates with extended circulating half-lives
AU2003213730A1 (en) 2002-03-01 2003-09-16 Bracco International B.V. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
EP1587944A4 (en) 2002-03-01 2007-03-21 Dyax Corp KDR AND VEGF / KDR BINDING PEPTIDES AND THEIR USE FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
ES2557286T3 (es) 2003-03-03 2016-01-25 Dyax Corp. Usos de péptidos que se unen específicamente al receptor del HGF (cMet)
US20050064045A1 (en) * 2003-09-18 2005-03-24 Sheng-Ping Zhong Injectable therapeutic formulations
EP1747026A1 (en) * 2004-05-18 2007-01-31 Siemens Aktiengesellschaft Biomolecular contrast agents for therapy control in radiation therapy with proton or ion beams
US7585492B2 (en) 2004-05-18 2009-09-08 Siemens Aktiengesellschaft Biomolecular contrast agents for therapy success and dose monitoring in radiation therapy with proton or ion beams
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
CN101317100A (zh) * 2005-11-29 2008-12-03 皇家飞利浦电子股份有限公司 使用磁共振区分结合和未结合造影剂
WO2007073792A1 (de) * 2005-12-19 2007-07-05 Bayer Schering Pharma Aktiengesellschaft Verfahren zur herstellung von 4,4-diphenylcyclohexanol
JP5563299B2 (ja) * 2006-08-17 2014-07-30 エピックス ファーマシューティカルズ，インコーポレイテッド リンパ系撮像方法
DE102006049821A1 (de) 2006-10-18 2008-04-24 Bayer Schering Pharma Aktiengesellschaft Metallchelate mit perfluoriertem PEG-Rest, Verfahren zu deren Herstellung, sowie deren Verwendung
US20100092389A1 (en) * 2008-10-10 2010-04-15 The General Hospital Corporation Detection of atherosclerosis using indocyanine green
US9423480B2 (en) * 2008-10-27 2016-08-23 The University Of Western Ontario System and method for magnetic resonance imaging
AR075900A1 (es) 2009-03-19 2011-05-04 Wyeth Llc Metodos para la preparacion de acidos (2-(8,9-dioxo-2,6-diazabiciclico (5.2.0) non-1(7)-en-2-il)etil) fosfonico y sus precursores.
WO2010121133A2 (en) 2009-04-17 2010-10-21 The General Hospital Corporation Multimodal imaging of fibrin
EP2531102B1 (en) 2010-02-02 2019-06-19 Koninklijke Philips N.V. Functional imaging
TW201514188A (zh) 2013-03-13 2015-04-16 Lantheus Medical Imaging Inc 製備釓磷維塞三鈉單水合物之方法
CA2899522C (en) 2013-04-08 2022-07-19 Sunnybrook Research Institute System and method for imaging biomarkers indicative of cardiac thermal ablation lesions
JP2015087167A (ja) * 2013-10-29 2015-05-07 キヤノン株式会社 画像処理方法、画像処理システム
WO2015089505A2 (en) 2013-12-13 2015-06-18 The Trustees Of The University Of Pennsylvania Coaxial ablation probe and method and system for real-time monitoring of ablation therapy
US20150344523A1 (en) 2014-05-05 2015-12-03 California Institute Of Technology Mutant akt-specific capture agents, compositions, and methods of using and making
WO2015196208A2 (en) 2014-06-20 2015-12-23 The General Hospital Corporation Collagen targeted imaging probes
CN107624115B (zh) 2015-03-16 2021-10-26 加州理工学院 肉毒神经毒素特异性捕获剂、组合物、使用方法和制造方法
EP3322716B1 (en) 2015-07-15 2025-02-12 California Institute of Technology Il-17f-specific capture agents and methods of using
US10383590B2 (en) 2015-09-28 2019-08-20 General Electric Company Methods and systems for adaptive scan control
US11884707B2 (en) 2016-09-29 2024-01-30 Regeneron Pharmaceuticals, Inc. Compositions for detection, inhibition and imaging of indoleamine 2, 3-dioxygenase 1 (IDO1) and methods of making and using same
WO2018085375A1 (en) 2016-11-01 2018-05-11 Ohio State Innovation Foundation Methods for the iodination of biomolecules
WO2018232345A1 (en) 2017-06-15 2018-12-20 Indi Molecular, Inc. Il-17f and il-17a-specific capture agents, compositions, and methods of using and making
US20190370956A1 (en) 2018-05-30 2019-12-05 General Electric Company Contrast imaging system and method
US11919972B2 (en) 2018-11-02 2024-03-05 Regeneron Pharmaceuticals, Inc. Peptide libraries with non-canonical amino acids
US11638764B2 (en) 2018-11-08 2023-05-02 Indi Molecular, Inc. Theranostic capture agents, compositions, and methods of using and making
US12201679B2 (en) 2019-04-05 2025-01-21 Institute For Systems Biology Epitope-targeted peptide immunostimulants
US12216122B2 (en) 2019-05-20 2025-02-04 Regeneron Pharmaceuticals, Inc. Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (IDO1)
US11414460B2 (en) 2019-07-19 2022-08-16 Institute For Systems Biology KRAS-specific capture agents, compositions, and methods of making and using
US12209142B2 (en) 2020-05-29 2025-01-28 Institute For Systems Biology SARS-CoV-2 epitope-targeted peptide immunostimulants
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250285A (en) 1985-05-08 1993-10-05 The General Hospital Corporation Hydroxy-aryl metal chelates for diagnostic NMR imaging
US5094848A (en) 1989-06-30 1992-03-10 Neorx Corporation Cleavable diphosphate and amidated diphosphate linkers
IT1269839B (it) 1994-05-26 1997-04-15 Bracco Spa Coniugati di acidi biliari, loro derivati con complessi metallici e relativi usi
TW319763B (pt) * 1995-02-01 1997-11-11 Epix Medical Inc
CA2539215A1 (en) 1995-02-01 1996-08-08 Epix Pharmaceuticals, Inc. Diagnostic imaging contrast agents with extended blood retention
DE19529512C2 (de) 1995-08-10 2000-11-23 Siemens Ag Verfahren zur Phasenkontrast-MR-Angiographie und Anordnung zur Durchführung des Verfahrens
DE19543785A1 (de) 1995-11-24 1997-05-28 Philips Patentverwaltung MR-Verfahren und Anordnung zur Durchführung des Verfahrens
BR9708470A (pt) * 1996-04-01 1999-04-13 Epix Medical Inc Agentes de contraste bioativados para formação de imagem para diagnósticos
IT1283650B1 (it) 1996-08-02 1998-04-23 Bracco Spa Chelati paramagnetici ad alta relassivita' in siero
US5919967A (en) 1997-04-11 1999-07-06 Epix Medical, Inc. Process for synthesizing phosphodiesters
CA2303426C (en) * 1997-10-02 2008-09-23 Epix Medical, Inc. Contrast-enhanced diagnostic imaging method for monitoring interventional therapies
IT1304501B1 (it) 1998-12-23 2001-03-19 Bracco Spa Uso di derivati di acidi biliari coniugati con complessi metallicicome "blood pool agents" per l'indagine diagnostica tramite risonanza

Also Published As

Publication number Publication date
US20050118103A1 (en) 2005-06-02
IS2041B (is) 2005-09-15
NO20001707D0 (no) 2000-04-03
IS5399A (is) 2000-03-10
IL134985A0 (en) 2001-05-20
AU9668698A (en) 1999-04-27
SK4842000A3 (en) 2000-11-07
NO321966B1 (no) 2006-07-31
DE69819925T2 (de) 2004-09-02
EP1019094B1 (en) 2003-11-19
HK1030744A1 (en) 2001-05-18
NZ503402A (en) 2002-03-01
WO1999017809A3 (en) 1999-05-20
ES2206996T3 (es) 2004-05-16
KR20010030854A (ko) 2001-04-16
HUP0101245A3 (en) 2003-10-28
CA2303426C (en) 2008-09-23
DK1019094T3 (da) 2004-02-16
NO20001707L (no) 2000-05-31
EP1019094A2 (en) 2000-07-19
CA2303426A1 (en) 1999-04-15
DE69819925D1 (de) 2003-12-24
US7175829B2 (en) 2007-02-13
AU742438C (en) 2003-05-22
JP2001518523A (ja) 2001-10-16
JP2006077020A (ja) 2006-03-23
PT1019094E (pt) 2004-03-31
HUP0101245A2 (hu) 2001-08-28
ATE254479T1 (de) 2003-12-15
AU742438B2 (en) 2002-01-03
WO1999017809A2 (en) 1999-04-15
US6861045B1 (en) 2005-03-01

Similar Documents

Publication Publication Date Title
BR9812716A (pt) Métodos para formação de imagem para diagnóstico de contraste intensificado para monitorar terapias interventivas
Getgood et al. The anterolateral complex of the knee: results from the International ALC Consensus Group Meeting
Sarmiento et al. Angular deformities and forearm function
Liu et al. Near-infrared cholecysto-cholangiography with indocyanine green may secure cholecystectomy in difficult clinical situations: proof of the concept in a porcine model
Zhang et al. Pavlov’s pain: the effect of classical conditioning on pain perception and its clinical implications
EP1007114A4 (en) CANNUM WITH POINTED ACCESS POINTS
de Silva et al. Nerve root hypertrophy in chronic inflammatory demyelinating polyneuropathy
Matthews et al. A biomechanical study of rabbit patellar tendon: effects of steroid injection
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
EA199800881A1 (ru) Способ т1 - взвешенной магниторезонансной визуализации органов ретикуло-эндотелиальной системы
Sorbi et al. Clinical application of a new disposable lithotripter: a prospective multicenter study
EP1531906A4 (en) NEW MEANS FOR THE IDENTIFICATION OF AGENTS FOR THE MODULATION OF RETINAL BLOOD VESSEL FUNCTION AND PERIZYTEN FUNCTION AND DIAGNOSTIC AND THERAPEUTIC APPLICATION THEREFOR
Gibbins et al. Sympathetic vasoconstrictor neurons projecting from the guinea-pig superior cervical ganglion to cutaneous or skeletal muscle vascular beds can be distinguished by soma size
WO2005030265A3 (en) Optical imaging of endometriosis
Petit Jr et al. Degos disease: neurologic complications and cerebral angiography
Giers et al. Jeannette Wilkins Award: can locally delivered gadolinium be visualized on MRI? A pilot study
Centeno How to obtain an SI joint arthrogram 90% of the time in 30 seconds or less
Kadar et al. Dynamic Tendon Grip (DTG™) novel knot array compared to traditional sutures for zone two flexor tendon injury–a biomechanical feasibility study
Bianchi et al. Ultrasound appearances of complications after arthroscopic anterior cruciate ligament reconstruction
Bertilson et al. Withdrawal, matching, withdrawal‐matching, and variable‐matching strategies in reducing attack‐instigated aggression
Mohammed et al. Axillary artery occlusion by distal biceps tendon avulsion leading to compartment syndrome in the arm: A rare case report
Warner Refugees, UNHCR and Human Rights: Current Dilemmas of Conflicting Mandates
Luque et al. Cotard's syndrome in the elderly: Historical and clinical aspects
Bosman Why conscience makes cowards of us all: a Classical perspective
Schiller Jirí Procháska: On the 250th Anniversary of his Birt

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]